| Drug Name |
Octreotide |
| Drug ID |
BADD_D02412 |
| Description |
Acromegaly is a disorder caused by excess growth hormone (GH), increasing the growth of body tissues and causing metabolic dysfunction.[L14501] In most cases, it results from an anterior pituitary growth hormone-releasing tumor. Typically, the feet, hands, and face grow abnormally large; organomegaly and insulin resistance may also occur. Acromegaly is a life-threatening disease requiring life-long management.[L14501]
Octreotide is a long-acting drug with pharmacologic activities that mimic those of the natural hormone, somatostatin, which inhibits the secretion of growth hormone.[L14513] Additionally, it is used for the treatment of acromegaly and symptoms arising from various tumors, including carcinoid tumors and vasoactive intestinal tumors (VIPomas).[L14513] In the past, octreotide has been administered solely by injection. On June 26, 2020, the first approved delayed-release oral somatostatin analog, Mycapssa, received FDA approval for the long term maintenance treatment of acromegaly. This drug was developed by Chiasma Inc.[L14495,L14507,L14528] |
| Indications and Usage |
For treatment of acromegaly and reduction of side effects from cancer chemotherapy |
| Marketing Status |
Not Available |
| ATC Code |
H01CB02 |
| DrugBank ID |
DB00104
|
| KEGG ID |
D00442
|
| MeSH ID |
D015282
|
| PubChem ID |
448601
|
| TTD Drug ID |
D02XIY
|
| NDC Product Code |
62147-0206; 35207-0002; 52416-118; 41524-0007; 52416-109; 69880-120 |
| Synonyms |
Octreotide | SMS 201-995 | SMS 201 995 | SMS 201995 | SM 201-995 | SM 201 995 | SM 201995 | Sandoz 201-995 | Sandoz 201 995 | Sandoz 201995 | Compound 201-995 | Compound 201 995 | Compound 201995 | SAN 201-995 | SAN 201 995 | SAN 201995 | Octreotide Acetate | Octreotide Acetate Salt | Sandostatine | Sandostatin |
